Common NameMDA-19CAS Number1048973-47-2Molecular Weight349.426Density1.2±0.1 g/cm3Boiling PointN/AMolecular FormulaC21H23N3O2Melting PointN/AMSDSN/AFlash PointN/A
Use of MDA-19
MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM. IC50 Value: 43.3 nM(Ki)Target: CB2 receptorin vitro: MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 +/- 10.3 vs 162.4 +/- 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 +/- 2.1 vs 1130 +/- 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3',5'-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, in vivo: MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity.
Names
NameN'-(1-Hexyl-2-oxoindolin-3-ylidene)benzohydrazideSynonymMore Synonyms
MDA-19 Biological Activity
DescriptionMDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM. IC50 Value: 43.3 nM(Ki)Target: CB2 receptorin vitro: MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 +/- 10.3 vs 162.4 +/- 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 +/- 2.1 vs 1130 +/- 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3',5'-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, in vivo: MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity.Related Catalog
Signaling Pathways >> GPCR/G Protein >> Cannabinoid Receptor
Research Areas >> Neurological Disease
Solvent
In Vitro:
DMSO : 14.29 mg/mL (40.90 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
In Vivo: 1.Add each solvent one by one: 10% DMSO 90% corn oil Solubility: ≥ 1.43 mg/mL (4.09 mM); Clear solution 2.Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in saline) Solubility: 1.43 mg/mL (4.09 mM); Suspended solution; Need ultrasonicSolubility1 mM2.8618 mL14.3090 mL28.6180 mL5 mM0.5724 mL2.8618 mL5.7236 mL10 mM0.2862 mL1.4309 mL2.8618 mLStoragePowder-20°C3 years 4°C2 yearsIn solvent-80°C6 months -20°C1 monthShippingRoom temperature in continental US; may vary elsewhereSMILESO=C(N/N=C1C(N(CCCCCC)C2=C\1C=CC=C2)=O)C3=CC=CC=C3References
Related MoleculesWIN 55212-2 mesylate | AM251 | Taranabant | SR144528 | Bay 59-3074 | Org 27569 | Otenabant | GW842166X | A-836339 | BML-190 | JD-5037 | (±)-SLV319 | Pregnenolone | Anandamide | 2-arachidonoylglycerol
Chemical & Physical Properties
Density1.2±0.1 g/cm3Molecular FormulaC21H23N3O2Molecular Weight349.426Exact Mass349.179016PSA61.77000LogP4.99Index of Refraction1.607
Safety Information
HS Code2933790090
Synthetic Route
Total: 1 Page
~78%
MDA-19
CAS#:1048973-47-2
Literature: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Patent: WO2009/12227 A1, 2009 ; Location in patent: Page/Page column 55-56 ; WO 2009/012227 A1
Precursor & DownStream
Precursor 2
DownStream 0
Customs
HS Code2933790090Summary2933790090. other lactams. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:9.0%. General tariff:20.0%
Synonyms
1,2,4-Triazine-6-carboxaldehyde,2,3,4,5-tetrahydro-3,5-dioxoO-benzylfluorescein benzyl esterdibenzylfluoresceinO,O'-DibenzylfluoresceinMDA-19N'-[(3Z)-1-Hexyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazideBenzoic acid, 2-[(3Z)-1-hexyl-1,2-dihydro-2-oxo-3H-indol-3-ylidene]hydrazideMDA 19
Use of MDA-19
MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM. IC50 Value: 43.3 nM(Ki)Target: CB2 receptorin vitro: MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 +/- 10.3 vs 162.4 +/- 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 +/- 2.1 vs 1130 +/- 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3',5'-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, in vivo: MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity.